SNS23

SNS23 is an investigational **lentiviral globin gene therapy vector** developed in the Memorial Sloan Kettering and San Rocco Therapeutics program for hemoglobinopathies, particularly **beta-thalassemia** and potentially **sickle cell disease**. Publicly available information indicates SNS23 is a modified successor to the earlier TNS9 globin vector platform and is designed to deliver a therapeutic **beta-globin expression cassette** into autologous hematopoietic stem cells so that patients can produce functional hemoglobin after ex vivo gene transfer and reinfusion. The exact final commercial product configuration, transgene cassette details, conditioning regimen, and clinical status are not well documented in standard public drug databases, so SNS23 is best characterized as a **preclinical or early translational gene therapy vector construct** rather than an approved drug product.

Other names

SNS23 vectorSNS-23 vectorSNS 23 vectorSNS23 vectorsSNS-23 vectorsSNS 23 vectors